Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IDIS Pharma
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.
The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.
Extending its business in continental Europe, in niche generics and in the further development of unlicensed medicines are some of the drivers of Clinigen's latest proposed acquisition.
- Other Names / Subsidiaries
- Idis Group Holdings Limited